Bharat Biotech releases Phase 3 trial data for Covaxin, claims 77.8% efficacy

The trial data also indicated that the vaccine was effective against the Delta variant of the virus

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3h9Hlk5
via IFTTT